By annette
How does Costa Rica perform in cancer care compared with national targets and Latin American OECD peers? This dashboard-style report provides a visual and quantitative overview of selected performance indicators across governance, cancer burden, economic burden, prevention, early detection, diagnosis and coordinated care, and access to innovative medicines. The analysis draws on both national and …
By annette
Ovarian cancer remains one of the most challenging cancers, with rather low survival outcomes and it being the deadliest gynecologic cancer type in Western countries. IHE has developed a new fact sheet providing a concise overview of ovarian cancer, covering disease burden, economic impact, prevention, detection, diagnosis, treatment innovation, quality of life, and policy priorities. …
By annette
Swedish cancer care is undergoing a paradigm shift, driven by rising number of new cancer cases, improved survival rates and advances in medical technology, creating new demands on healthcare capacity, workforce sustainability and long-term planning. In this report, we examine the challenges that Swedish cancer care faces as patterns of care demand continue to change.
By annette
Study on the cost savings and quality-of-life gains associated with the use of an AI-powered digital tool for self-management of chronic pain has recently been published in Pain Medicine.
By annette
As part of IHE’s work on cancer policy, Andrea Manzano recently visited the Dominican Republic to present IHE’s policy brief on cervical cancer in the country during May 25–29. The visit provided an important opportunity to share the findings of the brief across several key settings and to engage in discussions on how cervical cancer …
By annette
On the sidelines of the 79th World Health Assembly in Geneva last week, IHE contributed to two important discussions on how evidence, data, and accountability can support measurable progress in global health. Together with the Lung Cancer Policy Network and MSD, IHE hosted the workshop “Operationalizing the Lung Cancer Agenda: A Pathway to Measurable Progress.” …
By annette
with a poster titled “Perspective Mismatch and Static Assumptions: Re-Thinking How Drug Prices Are Specified in U.S. Economic Analyses The U.S. Second Panel on Cost-Effectiveness and the ISPOR Drug Cost Task Force recommend that prices in economic evaluations reflect stakeholder “opportunity costs”. In practice, this is frequently violated: (1) price metrics often fail to reflect …
By annette
Cancer is the leading cause of death in Slovenia, placing a significant and growing burden on patients, families, and the healthcare system. While Slovenia has made notable strides — with cancer mortality declining steadily over two decades and five-year survival reaching 61% — challenges remain in prevention, data infrastructure, workforce capacity, and equitable access to …
By annette
At the 14th Adriatic Congress of Pharmacoeconomics and Outcomes Research, held in Brijuni (Croatia) on 23–25 April, Thomas Hofmarcher and Urška Kosir were contributing to key discussions on how to translate evidence into better patient access across Central and Eastern Europe. Thomas presented around the question “Are we investing enough in cancer care – and does …
By annette
Despite having one of the highest cervical cancer burdens in the EU, Romania has shown real momentum for change. Recent legislative progress on HPV vaccination, together with the adoption of a national screening methodology aligned with EU recommendations, signals a strong and growing political commitment. This new IHE-report presents a clear, evidence-based roadmap to support …